Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality

BACKGROUND: Remdesivir is approved by the US Food and Drug Administration for the treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been shown to shorten time to recovery and improve clinical outcomes in randomized trials. METHODS: This was the final day 28 comparat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Open Forum Infect Dis
Autori principali: Olender, Susan A, Walunas, Theresa L, Martinez, Esteban, Perez, Katherine K, Castagna, Antonella, Wang, Su, Kurbegov, Dax, Goyal, Parag, Ripamonti, Diego, Balani, Bindu, De Rosa, Francesco G, De Wit, Stéphane, Kim, Shin-Woo, Diaz, George, Bruno, Raffaele, Mullane, Kathleen M, Lye, David Chien, Gottlieb, Robert L, Haubrich, Richard H, Chokkalingam, Anand P, Wu, George, Diaz-Cuervo, Helena, Brainard, Diana M, Lee, I-Heng, Hu, Hao, Lin, Lanjia, Osinusi, Anu O, Bernardino, Jose I, Boffito, Marta
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2021
Soggetti:
Major Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8244650/
https://ncbi.nlm.nih.gov/pubmed/34282406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofab278
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi